CURIS INC
CRIS$25M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaLEXINGTON
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 15, 2026
15wMarket Overview
Stock performance and key metrics
CRIS News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
CUDC-907
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Emavusertib
Acute Myelogenous Leukemia
Ibrutinib
Relapsed Hematologic Malignancy
Zanubrutinib
Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CUDC-907 | Phase 2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | - | - |
Emavusertib | Phase 2 | Acute Myelogenous Leukemia | - | - |
Ibrutinib | Phase 2 | Relapsed Hematologic Malignancy | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply